The Journal of Allergy and Clinical Immunology
Volume 122, Issue 3 , Pages 529-536.e17 , September 2008

Genetic variation in immune signaling genes differentially expressed in asthmatic lung tissues

  • Karine Tremblay, MSc

      Affiliations

    • Hôpital Laval, Université Laval, Quebec, Canada
    • Département des sciences fondamentales, Université du Québec à Chicoutimi, Saguenay, Quebec City, Canada
    • ,
  • Denise Daley, PhD

      Affiliations

    • James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Annie Chamberland, MSc

      Affiliations

    • Département des sciences fondamentales, Université du Québec à Chicoutimi, Saguenay, Quebec City, Canada
    • ,
  • Mathieu Lemire, PhD

      Affiliations

    • Ontario Institute for Cancer Research, Toronto, Ontario, Canada
    • ,
  • Alexandre Montpetit, PhD

      Affiliations

    • McGill University and the Genome Quebec Innovation Centre, Montreal, Quebec, Canada
    • ,
  • Michel Laviolette, MD

      Affiliations

    • Hôpital Laval, Université Laval, Quebec, Canada
    • ,
  • Arthur W. Musk, MD

      Affiliations

    • Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia
    • ,
  • Alan L. James, MD

      Affiliations

    • Western Australian Sleep Disorders Research Institute, Sir Charles Gairdner Hospital, Nedlands, Australia
    • ,
  • Moira Chan-Yeung, PhD

      Affiliations

    • Occupational and Environmental Lung Disease Unit, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Allan Becker, MD

      Affiliations

    • Department of Pediatrics and Child Health, Manitoba Centre for Health Policy, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    • ,
  • Anita L. Kozyrskyj, BScPhm, PhD

      Affiliations

    • Department of Pediatrics and Child Health, Manitoba Centre for Health Policy, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    • Faculty of Pharmacy and the Department of Community Health Sciences, Manitoba Centre for Health Policy, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    • ,
  • Andrew J. Sandford, PhD

      Affiliations

    • James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Thomas J. Hudson, MD

      Affiliations

    • Ontario Institute for Cancer Research, Toronto, Ontario, Canada
    • ,
  • Peter D. Paré, MD

      Affiliations

    • James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Catherine Laprise, PhD

      Affiliations

    • Département des sciences fondamentales, Université du Québec à Chicoutimi, Saguenay, Quebec City, Canada
    • University of Montreal Community Genomic Medicine Centre, Chicoutimi University Hospital, Saguenay, Quebec City, Canada
    • Corresponding Author InformationReprint requests: Catherine Laprise, PhD, Université du Québec à Chicoutimi, 555 boulevard de l'Université, Saguenay, Quebec, G7H 2B1, Canada.

Received 10 December 2007 ,Revised 14 April 2008 ,Accepted 23 May 2008.

  • Image Result

    LD pattern for ALOX15. A, ALOX15 LD pattern in the SLSJ familial sample. B, ALOX15 LD pattern in the CAPPS cohort. C, ALOX15 LD pattern in the SAGE cohort. D, ALOX15 LD pattern in the Busselton cohort

    LD pattern for ALOX15. A, ALOX15 LD pattern in the SLSJ familial sample. B, ALOX15 LD pattern in the CAPPS cohort. C, ALOX15 LD pattern in the SAGE cohort. D, ALOX15 LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for CD14. A, CD14 LD pattern in the SLSJ familial sample. B, CD14 LD pattern in the CAPPS cohort. C, CD14 LD pattern in the SAGE cohort. D, CD14 LD pattern in the Busselton cohort. The loca

    LD pattern for CD14. A, CD14 LD pattern in the SLSJ familial sample. B, CD14 LD pattern in the CAPPS cohort. C, CD14 LD pattern in the SAGE cohort. D, CD14 LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for CD27. A, CD27 LD pattern in the SLSJ familial sample. B, CD27 LD pattern in the CAPPS cohort. C, CD27 LD pattern in the SAGE cohort. D, CD27 LD pattern in the Busselton cohort. The loca

    LD pattern for CD27. A, CD27 LD pattern in the SLSJ familial sample. B, CD27 LD pattern in the CAPPS cohort. C, CD27 LD pattern in the SAGE cohort. D, CD27 LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for CXCL12. A, CXCL12 LD pattern in the SLSJ familial sample. B, CXCL12 LD pattern in the CAPPS cohort. C, CXCL12 LD pattern in the SAGE cohort. D, CXCL12 LD pattern in the Busselton cohort

    LD pattern for CXCL12. A, CXCL12 LD pattern in the SLSJ familial sample. B, CXCL12 LD pattern in the CAPPS cohort. C, CXCL12 LD pattern in the SAGE cohort. D, CXCL12 LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for IL2RB. A, IL2RB LD pattern in the SLSJ familial sample. B, IL2RB LD pattern in the CAPPS cohort. C, IL2RB LD pattern in the SAGE cohort. D, IL2RB LD pattern in the Busselton cohort. The

    LD pattern for IL2RB. A, IL2RB LD pattern in the SLSJ familial sample. B, IL2RB LD pattern in the CAPPS cohort. C, IL2RB LD pattern in the SAGE cohort. D, IL2RB LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for IL2RB. A, IL2RB LD pattern in the SLSJ familial sample. B, IL2RB LD pattern in the CAPPS cohort. C, IL2RB LD pattern in the SAGE cohort. D, IL2RB LD pattern in the Busselton cohort. The

    LD pattern for IL2RB. A, IL2RB LD pattern in the SLSJ familial sample. B, IL2RB LD pattern in the CAPPS cohort. C, IL2RB LD pattern in the SAGE cohort. D, IL2RB LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for IL2RB. A, IL2RB LD pattern in the SLSJ familial sample. B, IL2RB LD pattern in the CAPPS cohort. C, IL2RB LD pattern in the SAGE cohort. D, IL2RB LD pattern in the Busselton cohort. The

    LD pattern for IL2RB. A, IL2RB LD pattern in the SLSJ familial sample. B, IL2RB LD pattern in the CAPPS cohort. C, IL2RB LD pattern in the SAGE cohort. D, IL2RB LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for IL2RB. A, IL2RB LD pattern in the SLSJ familial sample. B, IL2RB LD pattern in the CAPPS cohort. C, IL2RB LD pattern in the SAGE cohort. D, IL2RB LD pattern in the Busselton cohort. The

    LD pattern for IL2RB. A, IL2RB LD pattern in the SLSJ familial sample. B, IL2RB LD pattern in the CAPPS cohort. C, IL2RB LD pattern in the SAGE cohort. D, IL2RB LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for IL7R. A, IL7R LD pattern in the SLSJ familial sample. B, IL7R LD pattern in the CAPPS cohort. C, IL7R LD pattern in the SAGE cohort. D, IL7R LD pattern in the Busselton cohort. The loca

    LD pattern for IL7R. A, IL7R LD pattern in the SLSJ familial sample. B, IL7R LD pattern in the CAPPS cohort. C, IL7R LD pattern in the SAGE cohort. D, IL7R LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for NOS2A. A, NOS2A LD pattern in the SLSJ familial sample. B, NOS2A LD pattern in the CAPPS cohort. C, NOS2A LD pattern in the SAGE cohort. D, NOS2A LD pattern in the Busselton cohort. The

    LD pattern for NOS2A. A, NOS2A LD pattern in the SLSJ familial sample. B, NOS2A LD pattern in the CAPPS cohort. C, NOS2A LD pattern in the SAGE cohort. D, NOS2A LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

  • Image Result
    LD pattern for SFRP1. A, SFRP1 LD pattern in the SLSJ familial sample. B, SFRP1 LD pattern in the CAPPS cohort. C, SFRP1 LD pattern in the SAGE cohort. D, SFRP1 LD pattern in the Busselton cohort. The

    LD pattern for SFRP1. A, SFRP1 LD pattern in the SLSJ familial sample. B, SFRP1 LD pattern in the CAPPS cohort. C, SFRP1 LD pattern in the SAGE cohort. D, SFRP1 LD pattern in the Busselton cohort. The location of each tested TagSNP along the chromosome is indicated in the upper part of the figure. The number in each diamond indicates the magnitude of LD (D′) as a percentage between respective pairs of SNPs. The strength of LD is depicted by progression of color: the color moves from red to white as D′ runs from 1 to 0.

 Supported by a grant from AllerGen NCE, Inc (http://www.allergen-nce.ca/), the Canadian Institutes of Health Research, the Respiratory Health Network of the Fonds de la recherche en santé du Québec, and the Western Australia Healthway. K.T. is an AllerGen PhD trainee and is supported by the Fondation de l'Université Laval studentship. D.D. is supported by grants from the Canadian Institutes of Health Research (CIHR), the Institutes of Gender and Health, Genetics, Population and Public Health, a CIHR STIHR IMPACT fellowship, and the Lung Association of British Columbia. A.C. is supported by the Fondation de l'Université du Québec à Chicoutimi studentship. A.L.K. is the recipient of a CIHR New Investigator award. A.S. is the chairholder of the Canada Research Chair (www.chairs.gc.ca) on genetic susceptibility to inflammatory disease. P.D.P. is a Michael Smith Foundation and Jacob Churg Scholar. T.J.H. is recipient of an Investigator Award from the CIHR and a Clinician-scientist Award in Translational Research from the Burroughs Wellcome Fund. C.L. is the chairholder of the Canada Research Chair on genetic determinants in asthma and the director of the Genetics platform of the Respiratory Health Network (RHN) of the Fonds de la recherche en santé du Québec (FRSQ).

 Disclosure of potential conflict of interest: D. Daley has received grant support from Allergan, the Canadian Institutes of Health Research (CIHR), and the Michael Smith Foundation for Health Research. M. Laviolette has received grant support from the CIHR, Asthmatx, AstraZeneca, GlaxoSmithKline, and Merck-Frosst. A. L. James has received grant support from Merck, Sharpe, and Dohme. A. L. Kozyrskyj has received grant support from AllerGen NCE and the CIHR. A. J. Sandford has received grant support from the Canadian CF Foundation. T. J. Hudson has received grant support from the Allergen Network, the CIHR, and the Burroughs Wellcome Fund. P. D. Paré has received grant support from Merck. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(08)01172-X

doi: 10.1016/j.jaci.2008.05.049

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 3 , Pages 529-536.e17 , September 2008

Article Tools

* Image Usage & Resolution